Valuation: Egetis Therapeutics AB

Market Cap 5.17B 512M 465M 429M 387M 731M 47.81B 759M 2.05B 25.8B 1.92B 1.88B 81.51B P/E 2026 *
131x
P/E 2027 * -43x
Enterprise Value 4.24B 419M 381M 352M 317M 599M 39.19B 622M 1.68B 21.15B 1.57B 1.54B 66.81B EV / Sales 2026 *
37.5x
EV / Sales 2027 * 8.69x
Free-Float
37.69%
Yield 2026 *
-
Yield 2027 * -
1 week+0.18%
Current month+10.54%
1 month+20.35%
3 months+56.84%
6 months+64.25%
Current year+108.24%
1 week 11.1
Extreme 11.1
11.2
1 month 8.96
Extreme 8.96
11.2
Current year 4.23
Extreme 4.23
11.2
1 year 3.62
Extreme 3.625
11.2
3 years 3.02
Extreme 3.025
11.2
5 years 3
Extreme 3.005
11.2
10 years 3
Extreme 3.005
22.6
Manager TitleAgeSince
Chief Executive Officer 50 16/06/2017
Director of Finance/CFO 47 31/12/2017
Chief Tech/Sci/R&D Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2017
Chairman 61 06/05/2024
Director/Board Member 63 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Executive/Senior Manager

-594 0.0001%
8/31/26 A Exercice

Chief Financial Officer

1,099 0.0002%
8/31/26 A Buy

Chief Operating Officer

1,099 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.18%+89.44%+126.94% 512M
+1.15%-2.81%+55.79%+71.12% 65.56B
-2.64%-1.13%+7.82%+88.90% 60.41B
-1.07%+0.30%+22.91%+86.76% 55.76B
+0.48%-2.53%+9.73%+121.14% 46.98B
-2.69%-6.38%+19.19%+25.79% 43.63B
-0.70%+4.93%+17.77%+45.03% 36.7B
-2.50%-15.73%+135.31%+662.73% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+1.98%-38.27%+390.98% 26.96B
Average -0.96%-2.06%+39.90%+167.88% 41B
Weighted average by Cap. -0.99%-2.21%+34.18%+147.52%

Financials

2026 *2027 *
Net sales 113M 11.18M 10.15M 9.37M 8.46M 15.96M 1.04B 16.58M 44.67M 564M 41.94M 41.06M 1.78B 512M 50.67M 45.99M 42.49M 38.33M 72.36M 4.73B 75.13M 202M 2.55B 190M 186M 8.07B
Net income 414M 40.97M 37.19M 34.36M 31M 58.51M 3.83B 60.76M 164M 2.07B 154M 150M 6.53B -120M -11.87M -10.77M -9.95M -8.98M -16.95M -1.11B -17.59M -47.42M -598M -44.52M -43.58M -1.89B
Net Debt -932M -92.23M -83.73M -77.35M -69.78M -132M -8.62B -137M -369M -4.65B -346M -339M -14.69B -720M -71.26M -64.69M -59.76M -53.91M -102M -6.66B -106M -285M -3.59B -267M -262M -11.35B
Projected Income Statement - Annual - Egetis Therapeutics AB
Logo Egetis Therapeutics AB
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Employees
61
Date Price Change Volume
17/11/26 SEK 11.12 0.00% 2,094,870
16/11/26 SEK 11.12 -0.71% 1,703,374
13/11/26 SEK 11.20 +0.72% 2,237,972
12/11/26 SEK 11.12 0.00% 2,578,051
11/11/26 SEK 11.12 +0.18% 5,182,684
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Egetis Therapeutics AB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
11.12SEK
Average target price
11.21SEK
Spread / Average Target
+0.83%
  1. Stock Market
  2. Stocks
  3. EGTX Stock